ოთხშაბათი, აპრილი 15, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Mineral

Rubidium

Rubidium (various salts)

Also known as: rubidium chloride, rubidium supplement

MODERATE RISK 5.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 5.0/10).

02

Safety Profile

Known Safety Concerns

  • No established human biological requirement
  • Mimics potassium -- cardiac and neuromuscular effects
  • CNS excitation at higher doses
  • No safe supplemental dose established

Contraindications

  • No established human biological requirement
  • Mimics potassium -- cardiac and neuromuscular effects
═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Rubidium is a trace alkali metal with no established essential function in human nutrition. Mimics potassium in biological systems. At pharmacological doses causes CNS excitation, hypertension, and potentially cardiac arrhythmia. No legitimate supplement use is supported by evidence.

Classification

Biological and Chemical Classification

Scientific Name
Rubidium (various salts)
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Mineral
Key Safety Concern No established human biological requirement
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Mineral
Main Safety Concern No established human biological requirement
Ingredient Rubidium
Scientific name Rubidium (various salts)
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Mineral
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No established human biological requirement
  • Mimics potassium -- cardiac and neuromuscular effects
  • CNS excitation at higher doses
  • No safe supplemental dose established
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Rubidium indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Rubidium
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Rubidium (various salts)
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 25 მარ 2026, 22:48

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Quantifying what matters: Clarifying the value of longitudinal flow gradients in [82Rb]rubidium-positron emission tomography myocardial perfusion imaging. ↗
    PMID 41866687 ↗
    Journal J Nucl Cardiol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41866687/
    Murphy NP et al.. Quantifying what matters: Clarifying the value of longitudinal flow gradients in [82Rb]rubidium-positron emission tomography myocardial perfusion imaging.. J Nucl Cardiol. 2026. PMID:41866687.
  2. Observational / other LOW evidence YELLOW
    Low-SWaP, tunable, and narrow-linewidth laser systems for deployable quantum technologies. ↗
    PMID 41845855 ↗
    Journal Opt Express
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41845855/
    Corato-Zanarella M et al.. Low-SWaP, tunable, and narrow-linewidth laser systems for deployable quantum technologies.. Opt Express. 2026. PMID:41845855.
  3. Observational / other LOW evidence YELLOW
    Saturated absorption spectroscopy for spatially resolved flow velocimetry. ↗
    PMID 41842408 ↗
    Journal Appl Opt
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41842408/
    Roy S et al.. Saturated absorption spectroscopy for spatially resolved flow velocimetry.. Appl Opt. 2026. PMID:41842408.
  4. Observational / other LOW evidence YELLOW
    Efficient and robust spatial-to-fiber coupling-with scalability to multimode quantum networks via the cascaded adaptive feedback control system. ↗
    PMID 41841848 ↗
    Journal Appl Opt
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41841848/
    Li Y et al.. Efficient and robust spatial-to-fiber coupling-with scalability to multimode quantum networks via the cascaded adaptive feedback control system.. Appl Opt. 2026. PMID:41841848.
  5. Observational / other LOW evidence YELLOW
    Resolution of Microvascular Ischemia Following Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: Evidence from Rubidium-82 PET. ↗
    PMID 41831813 ↗
    Journal J Nucl Cardiol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41831813/
    Melhem HB et al.. Resolution of Microvascular Ischemia Following Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: Evidence from Rubidium-82 PET.. J Nucl Cardiol. 2026. PMID:41831813.
  6. Observational / other LOW evidence YELLOW
    A Single-Cell Optically Pumped Intrinsic Gradiometer. ↗
    PMID 41829639 ↗
    Journal Sensors (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41829639/
    Zilinski N et al.. A Single-Cell Optically Pumped Intrinsic Gradiometer.. Sensors (Basel). 2026. PMID:41829639.
  7. Observational / other LOW evidence YELLOW
    Potassium Hexafluoroacetylacetonate Complex with 18-Crown-6 Ether as a Volatile Precursor of Molecular and Inorganic Films: Thermal and Structural Insights. ↗
    PMID 41828376 ↗
    Journal Int J Mol Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41828376/
    Kochelakov DV et al.. Potassium Hexafluoroacetylacetonate Complex with 18-Crown-6 Ether as a Volatile Precursor of Molecular and Inorganic Films: Thermal and Structural Insights.. Int J Mol Sci. 2026. PMID:41828376.
  8. Observational / other LOW evidence YELLOW
    Comparative study of Raman-coherence-assisted nonlinear magneto-optical rotation in D1 and D2 transitions using cold rubidium atoms. ↗
    PMID 41824695 ↗
    Journal Opt Lett
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41824695/
    Yin Y et al.. Comparative study of Raman-coherence-assisted nonlinear magneto-optical rotation in D1 and D2 transitions using cold rubidium atoms.. Opt Lett. 2026. PMID:41824695.
  9. Observational / other LOW evidence YELLOW
    Carrier Regulation and Interface Catalysis Synergy Enhance the Water Splitting Efficiency of Perovskite Photoelectrodes. ↗
    PMID 41818603 ↗
    Journal ACS Appl Mater Interfaces
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41818603/
    Li Y et al.. Carrier Regulation and Interface Catalysis Synergy Enhance the Water Splitting Efficiency of Perovskite Photoelectrodes.. ACS Appl Mater Interfaces. 2026. PMID:41818603.
  10. Observational / other LOW evidence YELLOW
    Calibrations of flat alkali acid phthalate crystals between 650 and 2400u2009u2009eV using synchrotron radiation. ↗
    PMID 41842518 ↗
    Journal Appl Opt
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41842518/
    Wu M et al.. Calibrations of flat alkali acid phthalate crystals between 650 and 2400u2009u2009eV using synchrotron radiation.. Appl Opt. 2025. PMID:41842518.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 5.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 5.0 / 10

Final GIRI Score for Rubidium. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

MODERATE RISK 5.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
5.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Moderate classification for Rubidium

GIRI Score 5.0 / 10

A score of 5.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge